Expanding Regenerative Therapies Will Open New Market Horizons

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

10 Sep 24

Updated

04 Aug 25

Views

129

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-37.4%

7D

-7.5%

Loading

1Y

-37.4%

7D

-7.5%

You can edit this narrative until Aug 5 12:00 AM. Then, changes will post as Updates.

Author's Valuation

US$53.8834.1% undervalued

AnalystConsensusTarget Fair Value

Shared on 04 Aug 25

Fair value Decreased 7.31%

Vericel’s consensus price target has been revised down from $58.12 to $53.88, primarily due to macro headwinds facing the MedTech sector such as Medicaid cuts, hospital closures, and negative investor sentiment despite some supportive market factors. Analyst Commentary Broad macro pressures, including Medicaid cuts and hospital closures due to recent legislation, are creating headwinds for the MedTech sector and impacting sentiment.

Shared on 30 Apr 25

Fair value Decreased 7.40%

Shared on 23 Apr 25

Fair value Decreased 0.79%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Decreased 2.48%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Decreased 0.18%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Increased 11%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 11 Mar 25

Fair value Decreased 1.47%

AnalystConsensusTarget Fair Value

US$53.88

34.1% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

16.80%

Biotech revenue growth rate

9.82%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.13%

Calculation

US$75.92m

Earnings '28

x

45.79x

PE Ratio '28

=

US$3.48b

Market Cap '28

US$3.48b

Market Cap '28

/

53.92m

No. shares '28

=

US$64.47

Share Price '28

US$64.47 Share Price '28

Discounted to 2025 @ 6.78% p.a.

=

US$52.96

Fair Value '25